Marilyn Kwan to Receptor, ErbB-2
This is a "connection" page, showing publications Marilyn Kwan has written about Receptor, ErbB-2.
Connection Strength
0.599
-
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov; 208(2):223-235.
Score: 0.239
-
Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015 Apr 14; 15:278.
Score: 0.125
-
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009; 11(3):R31.
Score: 0.083
-
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer. JAMA Netw Open. 2024 Mar 04; 7(3):e243345.
Score: 0.058
-
Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. Cancer. 2017 Jul 01; 123(13):2535-2542.
Score: 0.036
-
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
Score: 0.029
-
Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
Score: 0.029